Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma

about

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma

Item

http://www.wikidata.org/entity/Q57494289

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@en

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@nl

type

Item

label

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@en

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@nl

prefLabel

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@en

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@nl

P1476

Bendamustine, etoposide, and d ...... tation in non-Hodgkin lymphoma

@en

P2093

Adam M Greenbaum

http://www.w3.org/2001/XMLSchema#string

Ajay K Gopal

http://www.w3.org/2001/XMLSchema#string

Brian G Till

http://www.w3.org/2001/XMLSchema#string

Damian J Green

http://www.w3.org/2001/XMLSchema#string

Heather Rasmussen

http://www.w3.org/2001/XMLSchema#string

Leona A Holmberg

http://www.w3.org/2001/XMLSchema#string

Lihua E Budde

http://www.w3.org/2001/XMLSchema#string

Oliver W Press

http://www.w3.org/2001/XMLSchema#string

Ted Gooley

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma

Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity.

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

P304

223-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5045/BR.2018.53.3.223

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30310789

http://www.w3.org/2001/XMLSchema#string

P921

hematology

dexamethasone

P932

6170297

http://www.w3.org/2001/XMLSchema#string